Evidence map›Paper›PMID 37705524›Full record

ReviewMediterranean journal of hematology and infectious diseases2023

Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.

Raffaele Palmieri, Giovangiacinto Paterno, Flavia Mallegni, Federica Frenza, Ilenia De Bernardis, Federico Moretti, Elisa Meddi, Maria Ilaria Del Principe, Luca Maurillo, Adriano Venditti and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mediterranean journal of hematology and infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raffaele PalmieriDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Giovangiacinto PaternoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Flavia MallegniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Federica FrenzaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Ilenia De BernardisDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Federico MorettiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Elisa MeddiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Maria Ilaria Del PrincipeDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Luca MaurilloDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Adriano VendittiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Francesco BuccisanoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy-related myeloid neoplasms (t-MNs) encompass a specific sub-group of myeloid malignancies arising after exposure to radio/cytotoxic agents for the treatment of unrelated diseases. Such malignancies present unique features, including advanced age, high comorbidities burden, and unfavorable genetic profiles. All these features justify the need for a specific diagnostic work-up and dedicated treatment algorithms. However, as new classification systems recognize the unique clinical characteristics exhibited by t-MN patients, how to assess fitness status in this clinical setting is largely unexplored. Optimizing fitness assessment would be crucial in the management of t-MN patients, considering that factors usually contributing to a worse or better outcome (like age, comorbidities, and treatment history) are patient-specific. In the absence of specific tools for fitness assessment in this peculiar category of AML, the aim of this review is to describe all those factors related to patient, treatment, and disease that allow planning treatments with an optimal risk/benefit ratio.

Indexed as

Clinical evaluationT-AMLT-MN

Identifiers

PMID37705524
PMCPMC10497317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.